{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:18:32Z","timestamp":1792685912104,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Sigmund Freud Privatuniversit\u00e4t Wien"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p>Big data collected in large international cooperations allow validation of findings from traditional national patient cohorts for proving consistency. In this study we analyzed outcomes and phenotypic features of <jats:italic>TP53<\/jats:italic>-mutated chronic myelomonocytic leukemia (CMML) patients in the Austrian biodatabase for CMML (ABCMML; <jats:italic>n<\/jats:italic>\u202f=\u2009322) and in the international platform cBIOPORTAL (<jats:italic>n<\/jats:italic>\u202f=\u2009399). The prevalences of <jats:italic>TP53<\/jats:italic> mutations were 1.58 and 3.66, respectively. Numerically, overall survival was shorter in <jats:italic>TP53<\/jats:italic>-mutated patients in both cohorts (ABCMML 10.0 vs. 30.0 months and cBIOPORTAL 8.9 vs. 34.5 months), but this was statistically significant only in the cBIOPORTAL cohort. Decreased hemoglobin values and the presence of blast cells in peripheral blood were significantly associated with <jats:italic>TP53<\/jats:italic> mutations in the cBIOPORTAL group but not in the ABCMML database. Our study indicates the necessity of sufficient patient numbers for the comparison of CMML patients regarding outcome and phenotype according to their molecular subtype, particularly in the case of rare mutations.<\/jats:p>","DOI":"10.1007\/s10354-025-01072-0","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:09:44Z","timestamp":1741151384000},"page":"302-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Features of TP53-mutated patients with chronic myelomonocytic leukemia in a\u00a0national (ABCMML) and international cohort (cBIOPORTAL)","Merkmale TP53-mutierter Patienten mit chronisch myelomonozyt\u00e4rer Leuk\u00e4mie in einer nationalen (ABCMML) und internationalen Kohorte (cBIOPORTAL)"],"prefix":"10.1007","volume":"175","author":[{"given":"Magdalena","family":"Grass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-7034","authenticated-orcid":false,"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"2","key":"1072_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett\u00a0JM, Catovsky\u00a0D, Daniel\u00a0MT, et\u00a0al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189\u201399.","journal-title":"Br J Haematol"},{"issue":"7","key":"1072_CR2","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman\u00a0JW, Harris\u00a0NL, Brunning\u00a0RD. The world health organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292\u2013302.","journal-title":"Blood"},{"issue":"5","key":"1072_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman\u00a0JW, Thiele\u00a0J, Arber\u00a0DA, et\u00a0al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"20","key":"1072_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, et\u00a0al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"11","key":"1072_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0RP, et\u00a0al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"7","key":"1072_CR6","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury\u00a0JD, Solary\u00a0E, Abla\u00a0O, et\u00a0al. The 5th\u00a0edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"1","key":"1072_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.25684","volume":"95","author":"MM Patnaik","year":"2020","unstructured":"Patnaik\u00a0MM, Tefferi\u00a0A. Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97\u2013115.","journal-title":"Am J Hematol"},{"issue":"3","key":"1072_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida\u00a0F, Kantarjian\u00a0HM, Smith\u00a0TL, et\u00a0al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a\u00a0retrospective analysis of 213 patients. Blood. 2002;99(3):840\u20139.","journal-title":"Blood"},{"issue":"14","key":"1072_CR9","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","volume":"118","author":"AM Jankowska","year":"2011","unstructured":"Jankowska\u00a0AM, Makishima\u00a0H, Tiu\u00a0RV, et\u00a0al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14):3932\u201341.","journal-title":"Blood"},{"issue":"24","key":"1072_CR10","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","volume":"28","author":"A Kohlmann","year":"2010","unstructured":"Kohlmann\u00a0A, Grossmann\u00a0V, Klein\u00a0HU, et\u00a0al. Next-generation sequencing technology reveals a\u00a0characteristic pattern of molecular mutations in 72.8\u202f% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. JCO. 2010;28(24):3858\u201365.","journal-title":"JCO"},{"issue":"19","key":"1072_CR11","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Kosmider\u00a0O, Renneville\u00a0A, et\u00a0al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J\u00a0Clin Oncol. 2013;31(19):2428\u201336.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1072_CR12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena\u00a0C, Gall\u00ec\u00a0A, Such\u00a0E, et\u00a0al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317.","journal-title":"Blood"},{"issue":"1","key":"1072_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40164-022-00284-z","volume":"11","author":"Y Nie","year":"2022","unstructured":"Nie\u00a0Y, Shao\u00a0L, Zhang\u00a0H, He\u00a0CK, Li\u00a0H, Zou\u00a0J, et\u00a0al. Mutational landscape of chronic myelomonocytic leukemia in chinese patients. Exp Hematol Oncol. 2022;11(1):32.","journal-title":"Exp Hematol Oncol"},{"issue":"17-18","key":"1072_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00508-019-1526-1","volume":"131","author":"K Geissler","year":"2019","unstructured":"Geissler\u00a0K, J\u00e4ger\u00a0E, Barna\u00a0A, et\u00a0al. The austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): a\u00a0representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr. 2019;131(17-18):410\u20138.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"1072_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2288-13-33","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston\u00a0P, Altman\u00a0DG. External validation of a\u00a0cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13(1):33.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"1072_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami\u00a0E, Gao\u00a0J, Dogrusoz\u00a0U, et\u00a0al. The cbio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"3","key":"1072_CR17","doi-asserted-by":"publisher","first-page":"e432650","DOI":"10.1200\/EDBK_432650","volume":"44","author":"V Santini","year":"2024","unstructured":"Santini\u00a0V, Stahl\u00a0M, Sallman\u00a0DA. TP53 mutations in acute leukemias and myelodysplastic syndromes: insights and treatment updates. Am Soc Clin Oncol Educ Book. 2024;44(3):e432650.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"1072_CR18","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2013.100","volume":"27","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Solary\u00a0E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27(7):1441\u201350.","journal-title":"Leukemia"},{"issue":"11","key":"1072_CR19","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1182\/bloodadvances.2024012565","volume":"8","author":"A Bataller","year":"2024","unstructured":"Bataller\u00a0A, Gener-Ricos\u00a0G, Almanza-Huante\u00a0E, Chien\u00a0KS, Urrutia\u00a0S, Bazinet\u00a0A, et\u00a0al. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a\u00a0therapy-related neoplasm. Blood Adv. 2024;8(11):2695\u2013706.","journal-title":"Blood Adv"},{"issue":"4","key":"1072_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bjh.19060","volume":"203","author":"G Montalban-Bravo","year":"2023","unstructured":"Montalban-Bravo\u00a0G, Kanagal-Shamanna\u00a0R, Li\u00a0Z, Hammond\u00a0D, Chien\u00a0K, Rodriguez-Sevilla\u00a0JJ, et\u00a0al. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023;203(4):581\u201392.","journal-title":"Br J Haematol"},{"issue":"8","key":"1072_CR21","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/s41375-023-01964-3","volume":"37","author":"M Gurney","year":"2023","unstructured":"Gurney\u00a0M, Mangaonkar\u00a0AA, Lasho\u00a0T, et\u00a0al. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia. 2023;37(8):1753\u20136.","journal-title":"Leukemia"},{"issue":"3","key":"1072_CR22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/leu.2015.304","volume":"30","author":"DA Sallman","year":"2016","unstructured":"Sallman\u00a0DA, Komrokji\u00a0R, Vaupel\u00a0C, et\u00a0al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30(3):666\u201373.","journal-title":"Leukemia"},{"issue":"21","key":"1072_CR23","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/bloodadvances.2021004755","volume":"5","author":"N Radakovich","year":"2021","unstructured":"Radakovich\u00a0N, Meggendorfer\u00a0M, Malcovati\u00a0L, et\u00a0al. A\u00a0geno-clinical decision model for the diagnosis of myelodysplastic syndromes. Blood Adv. 2021;5(21):4361\u20139.","journal-title":"Blood Adv"},{"issue":"12","key":"1072_CR24","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/blood-2018-08-867333","volume":"133","author":"C Cargo","year":"2019","unstructured":"Cargo\u00a0C, Cullen\u00a0M, Taylor\u00a0J, et\u00a0al. The use of targeted sequencing and flow cytometry to identify patients with a\u00a0clinically significant monocytosis. Blood. 2019;133(12):1325\u201334.","journal-title":"Blood"},{"issue":"1","key":"1072_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40537-021-00553-4","volume":"9","author":"K Batko","year":"2022","unstructured":"Batko\u00a0K, \u015al\u0119zak\u00a0A. The use of big data analytics in healthcare. J\u00a0Big Data. 2022;9(1):3.","journal-title":"J Big Data"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-025-01072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10354-025-01072-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-025-01072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:34:53Z","timestamp":1757144093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10354-025-01072-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":25,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1072"],"URL":"https:\/\/doi.org\/10.1007\/s10354-025-01072-0","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Grass and K.\u00a0Geissler declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}